Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Cash & Current Investments (2016 - 2026)

Arcus Biosciences has reported Cash & Current Investments over the past 10 years, most recently at $981.0 million for Q4 2025.

  • For Q4 2025, Cash & Current Investments changed 0.31% year-over-year to $981.0 million; the TTM value through Dec 2025 reached $981.0 million, changed 0.31%, while the annual FY2025 figure was $981.0 million, 0.31% changed from the prior year.
  • Cash & Current Investments for Q4 2025 was $981.0 million at Arcus Biosciences, up from $831.0 million in the prior quarter.
  • Over five years, Cash & Current Investments peaked at $1.2 billion in Q1 2022 and troughed at $499.0 million in Q4 2021.
  • A 5-year average of $910.5 million and a median of $961.5 million in 2023 define the central range for Cash & Current Investments.
  • On a YoY basis, Cash & Current Investments climbed as much as 423.82% in 2021 and fell as far as 32.95% in 2021.
  • Year by year, Cash & Current Investments stood at $499.0 million in 2021, then soared by 102.2% to $1.0 billion in 2022, then dropped by 24.78% to $759.0 million in 2023, then increased by 28.85% to $978.0 million in 2024, then rose by 0.31% to $981.0 million in 2025.
  • Business Quant data shows Cash & Current Investments for RCUS at $981.0 million in Q4 2025, $831.0 million in Q3 2025, and $911.0 million in Q2 2025.